Michael Hatty v. Western Industries-North, LLC
This text of Michael Hatty v. Western Industries-North, LLC (Michael Hatty v. Western Industries-North, LLC) is published on Counsel Stack Legal Research, covering New Jersey Superior Court Appellate Division primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
NOT FOR PUBLICATION WITHOUT THE APPROVAL OF THE APPELLATE DIVISION This opinion shall not "constitute precedent or be binding upon any court." Although it is posted on the internet, this opinion is binding only on the parties in the case and its use in other cases is limited . R. 1:36-3.
SUPERIOR COURT OF NEW JERSEY APPELLATE DIVISION DOCKET NO. A-3914-23
MICHAEL HATTY and SUSAN HATTY,
Plaintiffs-Appellants,
v.
WESTERN INDUSTRIES-NORTH, LLC, and GLOUCESTER TERMINALS, LLC,
Defendants-Respondents,
and
WESTERN EXTERMINATING COMPANY OF PENNSYLVANIA, INC., ROLLINS, INC., THE INDUSTRIAL FUMIGANT COMPANY, LLC, HOLT LOGISTICS CORP., PRODUCE SERVICES OF AMERICA, INC., and GMT REALTY, LLC,
Defendants. __________________________________
Argued January 26, 2026 – Decided February 19, 2026
Before Judges Sabatino, Natali and Bergman. On appeal from the Superior Court of New Jersey, Law Division, Camden County, Docket No. L-1685-19.
V. Paul Bucci, II (Laffey Bucci D’Andrea Reich & Ryan, LLP) of the Pennsylvania bar, admitted pro hac vice, argued the cause for appellants (Samuel I. Reich (Laffey Bucci D’Andrea Reich & Ryan, LLP) and V. Paul Bucci, II, attorneys; Samuel I. Reich and V. Paul Bucci, II, on the briefs).
Robert D. Fox argued the cause for respondent Gloucester Terminals, LLC (Manko, Gold, Katcher & Fox LLP, attorneys; Robert D. Fox, Shoshana (Suzanne Ilene) Schiller, and Danielle N. Bagwell, on the briefs).
Walter F. Kawalec, III, argued the cause for respondent Western Industries-North, LLC (Marshall Dennehey, PC, attorneys; Walter J. Klekotka and Walter F. Kawalec, III, on the briefs).
PER CURIAM
This case involves plaintiff Michael Hatty's long-term workplace
exposure to a toxic chemical and issues of medical causation. He and his spouse1
appeal from a series of trial court orders that ultimately dismissed their claims
against the two defendants, Gloucester Terminals, LLC ("Gloucester") and
1 Because the claim of Susan Hatty as a co-plaintiff is for loss of consortium, we generally use the term "plaintiff" in this opinion when it connotes an individual to refer singularly to Michael Hatty, unless the context indicates otherwise. Both plaintiffs should be understood to join in the legal arguments, despite this opinion's usage of the term "plaintiff" in the singular. A-3914-23 2 Western Industries-North, LLC ("Western"), on summary judgment and also
denied their opportunities to pursue punitive damages.
For the reasons that follow, we reverse summary judgment as to both
defendants but affirm the denial of punitive damages. We also affirm the trial
court's interpretation of a release that partially limits plaintiff's claims against
Gloucester. The case is remanded for a jury trial, subject to certain limitations
we set forth in this opinion.
I.
Because this case has not been tried, we describe the pertinent facts
subject to the testimony and other evidence that would be actually presented at
trial. We consider the pretrial record, as we must, in a light most favorable to
plaintiff. Brill v. Guardian Life Ins. Co. of Am., 142 N.J. 520, 523 (1995).
Plaintiff's Initial Work as an Expediter for Del Monte in Delaware Starting in 1998
Plaintiff testified at his deposition that he first started as a seasonal worker
in the fruit import industry in 1998 when he worked for the Del Monte
A-3914-23 3 company.2 The season generally started sometime in winter and lasted until
early summer. Plaintiff had to be rehired each season.
For the first three seasons when he was employed by Del Monte, plaintiff
worked at the Wilmington Port terminal in Delaware. Plaintiff recalled that
grapes, pears, and apples came into Wilmington. Plaintiff knew that the fruit at
Wilmington was fumigated overnight before workers came in the morning.
When working for Del Monte, plaintiff's job was known as an "expediter."
His specific duties entailed receiving an order from a truck, going into the
refrigerated area—referred to in this litigation as "cold storage facilities" or
"cold storage boxes"3—and "getting the right fruit" for the order and "putting it
on the truck."
Del Monte Moves Its Operations and Plaintiff's Job to Gloucester Terminal in 2001 or 2002
Around either 2001 or 2002, Del Monte moved its operations to the
Gloucester terminal in New Jersey and plaintiff began working there. The
Gloucester terminal has two sections from the central loading dock, Pier 8 and
2 Del Monte is not a defendant in this case, presumably because of the workers compensation statutory bar to employees suing their employers for negligence. See N.J.S.A. 34:15-8. 3 Some depositions also use the term "cooler." These terms all appear to refer to the same thing and are used interchangeably throughout the record. A-3914-23 4 Pier 9. Pier 8 is known as "Building 14" and Pier 9 is known as "Building 20."
Both Pier 8 and Pier 9 have warehouses, each consisting of a large open area
where fumigation is performed, referred to as "sheds," and several large,
refrigerated cold storage boxes.
When employed by Del Monte in New Jersey, plaintiff worked in
"Building 42" at the Gloucester terminal. Plaintiff confirmed that while
employed by Del Monte he only worked in Building 42 and never worked in the
central warehouses of Pier 8 and Pier 9 at the Gloucester terminal.
Plaintiff explained that his job for Del Monte was the same at the
Gloucester terminal as it had been at the Wilmington terminal. Plaintiff further
stated he did not receive any additional or new training when he started working
at the Gloucester terminal and that he specifically did not receive any training
in fumigation.
In the busy season, which ranged from the months of February through
April, plaintiff would arrive at the Gloucester terminal around 6:00 a.m. and
work until 8:30 p.m. According to plaintiff, the gate to the terminal would not
open in the morning "until they had the clearing for fumigation." Plaintiff
testified that in Del Monte's busy season, the fruit would be fumigated nearly
every night.
A-3914-23 5 When employed by Del Monte at the Gloucester terminal, plaintiff worked
both in the cold storage boxes and in the sheds of Building 42. Plaintiff stated
he would have to go into the shed if "your order had a pallet that was not in the
refrigerator yet, it had just come off the ship and it was still sitting, you had to
go out and get it [from the shed] and find it."
Plaintiff estimated his work involved five percent getting pallets from the
shed and ninety-five percent getting them from the cold storage areas to
facilitate loading the correct fruit pallets onto the trucks. He further estimated
that he would be in the cold storage boxes "for at least 45 minutes to an hour"
at a time before coming out for a break, which would only last for about "ten
minutes" before another truck came in to be loaded.
Plaintiff's 2003 Achilles Tendon Injury and September 2004 Settlement with Gloucester
In February 2003, while still working for Del Monte at the Gloucester
terminal, plaintiff fell on the loading dock while working and tore his Achilles
tendon.
A-3914-23 6 In July 2003, plaintiff and his wife filed a complaint in federal district
court against Gloucester, alleging negligence. On September 14, 2004, plaintiff
settled the federal case for $80,000 and entered into a release with Gloucester. 4
Free access — add to your briefcase to read the full text and ask questions with AI
NOT FOR PUBLICATION WITHOUT THE APPROVAL OF THE APPELLATE DIVISION This opinion shall not "constitute precedent or be binding upon any court." Although it is posted on the internet, this opinion is binding only on the parties in the case and its use in other cases is limited . R. 1:36-3.
SUPERIOR COURT OF NEW JERSEY APPELLATE DIVISION DOCKET NO. A-3914-23
MICHAEL HATTY and SUSAN HATTY,
Plaintiffs-Appellants,
v.
WESTERN INDUSTRIES-NORTH, LLC, and GLOUCESTER TERMINALS, LLC,
Defendants-Respondents,
and
WESTERN EXTERMINATING COMPANY OF PENNSYLVANIA, INC., ROLLINS, INC., THE INDUSTRIAL FUMIGANT COMPANY, LLC, HOLT LOGISTICS CORP., PRODUCE SERVICES OF AMERICA, INC., and GMT REALTY, LLC,
Defendants. __________________________________
Argued January 26, 2026 – Decided February 19, 2026
Before Judges Sabatino, Natali and Bergman. On appeal from the Superior Court of New Jersey, Law Division, Camden County, Docket No. L-1685-19.
V. Paul Bucci, II (Laffey Bucci D’Andrea Reich & Ryan, LLP) of the Pennsylvania bar, admitted pro hac vice, argued the cause for appellants (Samuel I. Reich (Laffey Bucci D’Andrea Reich & Ryan, LLP) and V. Paul Bucci, II, attorneys; Samuel I. Reich and V. Paul Bucci, II, on the briefs).
Robert D. Fox argued the cause for respondent Gloucester Terminals, LLC (Manko, Gold, Katcher & Fox LLP, attorneys; Robert D. Fox, Shoshana (Suzanne Ilene) Schiller, and Danielle N. Bagwell, on the briefs).
Walter F. Kawalec, III, argued the cause for respondent Western Industries-North, LLC (Marshall Dennehey, PC, attorneys; Walter J. Klekotka and Walter F. Kawalec, III, on the briefs).
PER CURIAM
This case involves plaintiff Michael Hatty's long-term workplace
exposure to a toxic chemical and issues of medical causation. He and his spouse1
appeal from a series of trial court orders that ultimately dismissed their claims
against the two defendants, Gloucester Terminals, LLC ("Gloucester") and
1 Because the claim of Susan Hatty as a co-plaintiff is for loss of consortium, we generally use the term "plaintiff" in this opinion when it connotes an individual to refer singularly to Michael Hatty, unless the context indicates otherwise. Both plaintiffs should be understood to join in the legal arguments, despite this opinion's usage of the term "plaintiff" in the singular. A-3914-23 2 Western Industries-North, LLC ("Western"), on summary judgment and also
denied their opportunities to pursue punitive damages.
For the reasons that follow, we reverse summary judgment as to both
defendants but affirm the denial of punitive damages. We also affirm the trial
court's interpretation of a release that partially limits plaintiff's claims against
Gloucester. The case is remanded for a jury trial, subject to certain limitations
we set forth in this opinion.
I.
Because this case has not been tried, we describe the pertinent facts
subject to the testimony and other evidence that would be actually presented at
trial. We consider the pretrial record, as we must, in a light most favorable to
plaintiff. Brill v. Guardian Life Ins. Co. of Am., 142 N.J. 520, 523 (1995).
Plaintiff's Initial Work as an Expediter for Del Monte in Delaware Starting in 1998
Plaintiff testified at his deposition that he first started as a seasonal worker
in the fruit import industry in 1998 when he worked for the Del Monte
A-3914-23 3 company.2 The season generally started sometime in winter and lasted until
early summer. Plaintiff had to be rehired each season.
For the first three seasons when he was employed by Del Monte, plaintiff
worked at the Wilmington Port terminal in Delaware. Plaintiff recalled that
grapes, pears, and apples came into Wilmington. Plaintiff knew that the fruit at
Wilmington was fumigated overnight before workers came in the morning.
When working for Del Monte, plaintiff's job was known as an "expediter."
His specific duties entailed receiving an order from a truck, going into the
refrigerated area—referred to in this litigation as "cold storage facilities" or
"cold storage boxes"3—and "getting the right fruit" for the order and "putting it
on the truck."
Del Monte Moves Its Operations and Plaintiff's Job to Gloucester Terminal in 2001 or 2002
Around either 2001 or 2002, Del Monte moved its operations to the
Gloucester terminal in New Jersey and plaintiff began working there. The
Gloucester terminal has two sections from the central loading dock, Pier 8 and
2 Del Monte is not a defendant in this case, presumably because of the workers compensation statutory bar to employees suing their employers for negligence. See N.J.S.A. 34:15-8. 3 Some depositions also use the term "cooler." These terms all appear to refer to the same thing and are used interchangeably throughout the record. A-3914-23 4 Pier 9. Pier 8 is known as "Building 14" and Pier 9 is known as "Building 20."
Both Pier 8 and Pier 9 have warehouses, each consisting of a large open area
where fumigation is performed, referred to as "sheds," and several large,
refrigerated cold storage boxes.
When employed by Del Monte in New Jersey, plaintiff worked in
"Building 42" at the Gloucester terminal. Plaintiff confirmed that while
employed by Del Monte he only worked in Building 42 and never worked in the
central warehouses of Pier 8 and Pier 9 at the Gloucester terminal.
Plaintiff explained that his job for Del Monte was the same at the
Gloucester terminal as it had been at the Wilmington terminal. Plaintiff further
stated he did not receive any additional or new training when he started working
at the Gloucester terminal and that he specifically did not receive any training
in fumigation.
In the busy season, which ranged from the months of February through
April, plaintiff would arrive at the Gloucester terminal around 6:00 a.m. and
work until 8:30 p.m. According to plaintiff, the gate to the terminal would not
open in the morning "until they had the clearing for fumigation." Plaintiff
testified that in Del Monte's busy season, the fruit would be fumigated nearly
every night.
A-3914-23 5 When employed by Del Monte at the Gloucester terminal, plaintiff worked
both in the cold storage boxes and in the sheds of Building 42. Plaintiff stated
he would have to go into the shed if "your order had a pallet that was not in the
refrigerator yet, it had just come off the ship and it was still sitting, you had to
go out and get it [from the shed] and find it."
Plaintiff estimated his work involved five percent getting pallets from the
shed and ninety-five percent getting them from the cold storage areas to
facilitate loading the correct fruit pallets onto the trucks. He further estimated
that he would be in the cold storage boxes "for at least 45 minutes to an hour"
at a time before coming out for a break, which would only last for about "ten
minutes" before another truck came in to be loaded.
Plaintiff's 2003 Achilles Tendon Injury and September 2004 Settlement with Gloucester
In February 2003, while still working for Del Monte at the Gloucester
terminal, plaintiff fell on the loading dock while working and tore his Achilles
tendon.
A-3914-23 6 In July 2003, plaintiff and his wife filed a complaint in federal district
court against Gloucester, alleging negligence. On September 14, 2004, plaintiff
settled the federal case for $80,000 and entered into a release with Gloucester. 4
Following his Achilles injury, plaintiff returned to work for Del Monte for
one additional season. After that, "they didn't rehire" him, signifying that
plaintiff's employment for Del Monte ended around 2006.
Plaintiff Returns to Work Around 2007 at the Gloucester Terminal Where Western Was the Fumigator
Around 2007, Produce Services of America ("PSA")5 hired plaintiff.6
While employed by PSA, he continued to work at the Gloucester terminal.
However, he worked in the Pier 8 and Pier 9 warehouses, which plaintiff refers
to as "central," rather than Building 42.
Defendant Western is a firm that provides fruit fumigation services. The
fumigation services at the Pier 8 and 9 warehouses were provided by Western.
4 We will discuss the terms and significance of that release in Part II(B), infra. 5 Plaintiffs named PSA as a co-defendant in this case. However, the trial court dismissed the claims against PSA, and PSA is not participating as a respondent in this appeal. 6 For sake of clarity in this opinion, we henceforth will use the year 2007 as the approximate year when plaintiff began working for PSA; the actual date may be verified at trial. A-3914-23 7 Plaintiff admitted that Western was not involved in providing fumigation
services in any of the facilities he worked in while he was employed by Del
Monte, including those at the Wilmington terminal, nor in Building 42 at the
Gloucester terminal.
The season for PSA began around October or November and lasted until
"[a]round the second week of June." The busy portion of the season was from
the "middle of January [until] May." During the busy season, plaintiff would
arrive at work around 7:30 a.m. and leave around 8:30 p.m.
Plaintiff testified that he served as an expediter when working for PSA
and that his job was "basically the same" as it had been at Del Monte. He would
get "an order from the truck driver, from the desk, grab the two forklift drivers "
and then go into the cold storage boxes to find the correct pallet of fruit to
"[make] sure the right fruit was on the order." After this had taken place, "[t]he
fork driver took [the pallets] out to the truck [and] put it on the truck." Plaintiff
did not handle the fruit himself.
As with his job at Del Monte, when working for PSA, plaintiff was in the
cold storage boxes at Pier 8 and Pier 9 for about forty-five minutes to an hour
per order. He would similarly only go into the sheds at Pier 8 and Pier 9 about
A-3914-23 8 "five percent of the time" "[i]f the fruit was out in the shed and was needed for
the truck."
According to plaintiff, he did not receive any training by PSA nor any
information about safety or fumigation. However, he acknowledged seeing and
reading a safety warning sign posted on the dock beside the cold storage boxes
when he worked for PSA. The jobsite sign used the term "off-gas," which
essentially refers to the fruit's emission of gaseous chemicals for a period of time
after it has been fumigated.
The sign stated that methyl bromide "can off-gas from the fumigated fruit
for several days" and that "[t]he most common effects of overexposure to
excessive off-gassing methyl bromide are headache, nausea, vomiting,
dizziness, blurred vision, poor coordination, and twitching." It moreover
cautioned that workers should "spend only as much time as necessary" in the
cold storage boxes "to get your job safely done."
Plaintiff acknowledged that he saw the warning sign on the wall, but did
not read it "in that detail." He nevertheless would go into the cold storage boxes
"and load[] the truck, [which] took whatever time it took." He said he "knew
[methyl bromide] was dangerous" but "thought it was okay" once he and the
other workers were given "the okay" to enter the cold storage boxes. Plaintiff
A-3914-23 9 said there were fans and ventilation going on in the cold storage boxes "all the
time."
Western's Fumigation Process at Gloucester
Describing the fumigation process at Piers 8 and 9, Timothy McNellis,
Gloucester's operations manager of those piers, stated at his deposition that
"anything that gets fumigated on" the Gloucester terminal at those piers "gets
methyl bromide." He said the methyl bromide itself was administered by
Western to the different commodities delivered to Pier 8 and Pier 9. He
explained that Western was hired "by the importers to fumigate their fruit,"
which in this case was PSA, "not by Gloucester Terminal."
Gloucester's manager Peter Inskeep confirmed that Western was the only
fumigator for Piers 8 and 9 since he began as Gloucester's operations manager
in 2012. The fumigation was done in the sheds of those piers and, according to
Inskeep, is regulated by the United States Department of Agriculture ("USDA").
Western's fumigation director Kurt Reichert stated at his deposition that
Western "did not have a contract specific with the [Gloucester T]erminal." and
that Gloucester did not pay Western.
The fumigation process was elaborated by Western's service supervisor
Michael Wisser at his deposition. Wisser explained that "in the warehouse
A-3914-23 10 there's a bunch of tarps up in the ceiling" and that those tarps come down to
cover the stacks of fruit on the floor of the sheds. A "heat exchanger" is then
used to "shoot the gas," referring to methyl bromide, into the tarps to fumigate
the fruit.
Wisser testified that fumigation would begin in the evening and last
through the overnight hours, usually ending "at the latest, [four] o'clock in the
morning." When fumigating the fruit, "all the doors" in the sheds are open.
The fruit venting process was detailed by Western technician Mark Gallo,
Jr. at his deposition. Gallo testified that methyl bromide would be put into the
stacks of fruit for "three hours" and then "[a]fter three hours, you would vent the
fruit for [another] three hours." Once fumigation was complete, a technician
would sample the air in the shed to ensure that methyl bromide levels were below
5 parts per million ("ppm") before allowing any workers into that area in the
morning.
Gloucester's operations director McNellis confirmed that once Western
cleared the sheds, "they'll let security know" and workers were then allowed to
enter the terminal, which was "usually before we show up for work." Once
fumigated, the fruit was moved to the cold storage boxes.
A-3914-23 11 Air Sampling and Testing
At first, air sampling for methyl bromide was only done in the sheds of
Pier 8 and Pier 9 where the actual fumigation occurred, not in the cold storage
boxes where plaintiff predominantly worked. That changed by 2012 when
stricter measures were adopted.
Michael Quigley, Gloucester's then-director of safety and loss control,
testified at his deposition that, around 2011, he was tasked "with joining with
the Maritime Exchange in developing and responding to the EPA 's [the
Environmental Protection Agency's] inquiry into how methyl bromide is being
handled in the different facilities." Quigley took part in "put[ting] in place a
Best Management Practices [("BMP")] for our terminal and do some readings in
additional locations of methyl bromide concentrations in the air."
When Quigley joined the task force, he learned "that the fruit after
fumigation . . . can still off-gas up to 72 hours." Based on this information,
Gloucester decided to start air sampling for methyl bromide in the cold storage
boxes of Pier 8 and Pier 9.
The OSHA 20 PPM Permissible Exposure Limit
Quigley stated that the Occupational Safety and Health Administration's
("OSHA's") "permissible exposure limit" for methyl bromide "is 20 parts per
A-3914-23 12 million." See 29 C.F.R. § 1910.1000(a) (denoted as "Table Z-1").7 He further
explained that Gloucester "set some voluntary lower limits for what would
require action on [their] part."
Adoption of the FASSOP Policy in February 2012 and Mitigation Procedures
When Gloucester first implemented a practice of air sampling for methyl
bromide in the cold storage boxes, Western did the sampling. According to
Western's fumigation director Reichert, Western did not provide air sampling in
cold storage boxes at any other location other than Pier 8 and Pier 9 of the
Gloucester terminal. He indicated that Western developed a site-specific policy
for monitoring of methyl bromide in the cold storage boxes at those two piers.
The policy was referred to "as the Fumigation Air Sampling Standard Operating
Procedures, 'FASSOP' for short."
As explained by Reichert, Western developed the FASSOP policy "[i]n
conjunction with Gloucester." The written version of FASSOP, dated February
12, 2012, states that "[a]ll air sampling" in the cold storage boxes "needs to be
done in the A[.]M[.], prior to anyone entering the coolers" and that "[r]eadings
will be recorded on the [s]ampling [l]og [s]heet."8 The policy directs that "[i]f
7 We discuss the regulation in more detail, infra, at Parts II(C) and (D). 8 The log sheets have not been included in the record. A-3914-23 13 readings are above 5ppm [Gloucester] will be notified, and they shall begin their
mitigation procedure." "Once the mitigation process has begun, air sampling
will resume until 2 sequential readings at 15 minute intervals are below 5ppm ."
The FASSOP additionally states that "[i]f readings are 10ppm or above
[Gloucester] will be notified" and "[a]ccess to area will be stopped and
mitigation procedure implemented by [Gloucester]" until "2 sequential readings
at 15 minute intervals are below 5ppm."
The Hours of Sampling
Operations Manager McNellis stated that Western would conduct the
sampling in the cold storage boxes at Pier 8 and Pier 9 "[b]etween 4:00 and 6:00
a.m." Reichert similarly confirmed that Gloucester had requested that Western
conduct sampling in the cold storage boxes for methyl bromide "in the morning"
and that Western employees would generally "go in 3:30 or so, 4:00 in the
morning to take readings."
Reichert testified that he "believe[d] there were a few occasions in 2016
and, again, in 2017" when Gloucester requested Western to conduct sampling in
the cold storage boxes in the afternoon hours. However, he recalled that such
afternoon testing was "intermittent."
A-3914-23 14 Mitigation When Readings Exceeded 5 ppm
Reichert explained that whoever took the samples in the cold storage
boxes from Western would contact McNellis to tell him the reading level. If the
level was "above the 5 [ppm, McNellis] would ask that we place fans in the
coolers to aerate the coolers." Likewise, Inskeep confirmed that "[i]f we had a
reading above 5 [ppm], we would ventilate" and "[i]f there was a reading above
10 [ppm], we would shut down the box."
Reichert further testified that Western "would not initiate anything on [its]
own without direction from [Gloucester]." He stated that Western had no
control over what Gloucester did regarding any mitigation measures if methyl
bromide levels were above the 5 and 10 ppm thresholds in the cold storage
boxes. Reichert asserted that, for Western, any methyl bromide reading "under
20 ppm is considered safe" and that the 5 and 10 ppm thresholds were site-
specific to Gloucester.
Western's expert industrial hygienist, Bernard D. Silverstein, reviewed the
sampling logs for the time that Western was taking the samples in the cold
storage boxes in Pier 8 and Pier 9. Silverstein concluded that "none of the
sampling data reviewed indicated any exposures above the OSHA standard of
20 ppm[,] which is the exposure limit for workers like [plaintiff]."
A-3914-23 15 Gloucester Takes Over the Sampling in 2017
According to Inskeep, around 2017, the tubing used in the cold storage
boxes of Piers 8 and 9 to obtain methyl bromide samples needed to be replaced.
That led Gloucester employees to take over the responsibility of conducting the
methyl bromide sampling in the cold storage boxes in place of Western.
Once Gloucester took over sampling in the cold storage boxes, Inskeep
stated it would "take one [sample] prior to the employees going in the boxes in
the morning, and then we would take one [sample] in the afternoon." McNellis
confirmed he started taking methyl bromide samples in the cold storage boxes
at Pier 8 and Pier 9 beginning in January 2017. He indicated he "got instructions
from USDA and Western Fumigation" on how to conduct the sampling. He
confirmed he would take samples "twice a day" in the cold storage boxes.
Knowledge of Off-Gassing
Most of the Gloucester and Western employees who were deposed
understood what off-gassing was with respect to methyl bromide. For instance,
Inskeep stated that "there is information out there that a product can absorb
fumigants for longer . . . and that as those products settle, that it can still release
residual methyl bromide." As described by Inskeep, Gloucester was "always
A-3914-23 16 concerned, which is why we told employees don't eat the fruit, you have to wash
the fruit."
Reichert similarly stated that he understood that "after a commodity is
fumigated with methyl bromide, an unknown amount could be absorbed by
packaging or the product itself," but stated it would only be a "[v]ery small
amount" "[i]n the parts per million level." McNellis comparably stated that he
understood that "during the course of the day . . . there is [methyl bromide] gas
escaping from some of these boxes" after fumigation and that he knew of this
concept before January 2017.
Plaintiff Begins Noticing Symptoms in January 20179
According to plaintiff's testimony, around January 2017, he began
experiencing cramping in his right hand. His right hand "would lock" in a "claw-
like" position. He stated this cramping would happen "constantly."
In late February to early March 2017, plaintiff also began to experience
headaches. He said he had them at home and while at work. He indicated he
would get them "two, three times a day, five days a week." Plaintiff
9 Although plaintiff's medical condition is presumptively private, we refer to his symptoms and diagnoses by necessity given the nature of the issues on appeal. R. 1:38-1A. A-3914-23 17 communicated that he "would get dizzy, like off-balance" from the headaches.
He believed these headaches were tied to his exposure to methyl bromide.
Other symptoms soon manifested. Around the end of March and into
April and May 2017, plaintiff began having nausea and getting lightheaded,
which he experienced at home and at work. He recalled the nausea would "last
an hour, 40 minutes" and would occur several times per week. He also
experienced "burning of the lips every time [he] was in the cooler" which would
last for "[a]t least an hour" after he left work. The burning was said to be
"constant." However, when he went home, the burning would stop. Plaintiff
also experienced dizziness around the same time, as well as back and hip pain.
Plaintiff Consults His Family Doctor in April 2017 and His Blood Test Is Highly Abnormal
Due to these symptoms, in April 2017, plaintiff went to his family
physician, Dr. Joseph Mangel, for a blood test. Plaintiff said that "the gossip on
the dock" was that workers at the Gloucester terminal were "getting tested
for . . . methyl bromide" and that others were getting sick.
When the blood test results came back from the laboratory, Dr. Mangel
told plaintiff "that the counts [for methyl bromide] w[ere] six times higher than
normal" in his blood. Dr. Mangel referred plaintiff to heart and lung doctors,
who he thought should be consulted about the exposure.
A-3914-23 18 Referral to Dr. Katz, a Neurologist
Around that time, Dr. Mangel also referred plaintiff to a neurologist, Olga
A. Katz. As recalled by plaintiff, Dr. Katz recommended that he not work for
PSA at the Gloucester terminal anymore. Plaintiff accordingly told PSA "the
next day" that he would not continue working there, showing his supervisor at
PSA his blood test results.
Plaintiff Stops Working at Gloucester in May 2017, But Some Symptoms Persist
Plaintiff stopped working at the Gloucester terminal in May 2017 and has
not worked since.
Some of his symptoms then began to abate. He stated his headaches began
to get better "[a]bout six, seven months after [he] was out of work." His nausea
began to subside "a good eight months" after he stopped working at the
Gloucester terminal. His dizziness ceased that summer after he stopped
working.
Plaintiff's function of his right hand, however, continued to be impaired.
He testified that Dr. Katz provided electronic treatment for his right hand, but
that his right "hand just do[es]n't work" and that his middle three fingers "don't
bend" and "don't straighten out." However, plaintiff noted the cramping in his
right hand had gotten better since leaving work.
A-3914-23 19 Beyond physical symptoms, plaintiff described himself as "very, very
moody," believing this moodiness to be an effect from methyl bromide exposure.
He further explained that he started having memory difficulties around this time,
and that he would often "start conversations, and then in the middle . . . just stop
them, for some reason" without realizing what he was doing.
Dr. Katz's Neurology Expert Report
In May 2021, Dr. Katz authored an expert report addressing plaintiff's
"diagnosis, histories, current impression and prognosis." Her report noted that
methyl bromide "is classified as a highly toxic substance" by the United States
Centers for Disease Control and Prevention ("CDC") and that it is "a colorless,
odorless gas used to fumigate agricultural fields and some produce ."
Dr. Katz stated that, according to the EPA, "a respirator is required if the
acceptable air concentration level of methyl bromide in the working area, as
measured by a direct-reading detector device, exceeds 5 ppm (20 mg/m 3)" and
that "exposure to toxic levels may occur without warning or detection by the
user." Her report noted that, similarly, the National Institute for Occupational
Safety and Health ("NIOSH") "recommends as part of its carcinogen policy that
the 'most protective' respirators be worn for methyl bromide at any detectable
concentration."
A-3914-23 20 Dr. Katz's report detailed several studies on methyl bromide exposure.
She noted that a 2011 CDC study had "established that two poisoned agricultural
workers [who] were exposed intermittently to methyl bromide over several
months as part of their job inspecting produce . . . revealed disabling neurologic
symptoms (e.g., ataxia, memory difficulties, and dizziness) and elevated serum
bromide concentrations serving as proof of exposure." Her report also detailed
another CDC investigation from 2015 that reported "three people developed life-
threatening illness [two] days after their dwelling was fumigated with the
exposure to relatively reduced levels of the residue of methyl bromide confirmed
as the causative agent."
Commenting on the difficulties in detecting the substance's toxicity, Dr.
Katz's report stated that "[d]ue to its odorless and colorless nature that prevents
the potential victim from recognizing the danger, even one-time exposure to
methyl bromide may cause severe toxicity." She noted that was the case in
"another 2015 report on an accidental one-time exposure that caused multi-organ
failure and the victim to spend two months in intensive care."
According to Dr. Katz's expert report, "the use of methyl bromide is
associated with numerous cases of acute and chronic toxicity to human beings
and is two-fold." At first, "methyl bromide is toxic, primarily to central and
A-3914-23 21 peripheral nervous system[s] due to its affinity to neuronal DNA." But then, "as
the compound enters into chemical reactions with biological substances, toxicity
of its constituent components, the methyl group and the bromide (bromide ion)
is combined via . . . susceptible biologic compounds such as DNA and proteins,
and the direct toxicity of the bromide (bromide ion) that is especially
pronounced in the peripheral and autonomic nervous system."
Dr. Katz explained that "[d]epending on the specific vulnerabilities of the
victim, methyl bromide toxicity may present with a wide spectrum of central
and peripheral neurologic symptomology, from ataxia, memory deficits, and
visual disturbances, to autonomic neuropathy involving cardiac nerves and
peripheral neuropathy of one or more extremities."
Further, Dr. Katz underscored that the "initial measurement of bromide
levels" in plaintiff's blood in April 2017 "was extremely high at 7.2 mg/dL" with
the toxicity level being 1.2 mg/dL. She noted that even after plaintiff had been
"avoiding the exposure, the levels of bromide remained elevated above the toxic
level" in a later blood test in late May 2017. She added that cases reported by
the CDC indicate that "life-threatening exposure was associated with bromide
levels less than 10 mg/dL, similar to the levels measured in [plaintiff's] first
laboratory workup."
A-3914-23 22 In sum, Dr. Katz opined that plaintiff's "acute symptoms were concordant
with methyl bromide poisoning, such as paresthesia (abnormal sensation) in the
face and lips due to acute toxicity in the sensory nerves, and frequent episodic
headaches associated with . . . paresthesia of the lower back and muscle
weakness of the lower extremities." She stated these symptoms "further
developed with muscle weakness of the right thumb and the third and fourth
fingers to the point of involuntary flexion."
Dr. Katz further opined that "[b]oth the development of symptoms and the
improvement after leaving the contaminated area are fully consistent with acute
poisoning with methyl bromide as described in the literature." (Emphasis
added). She also noted that plaintiff had "[o]bjective muscle strength and bulk
changes" [that] "have been noted by several specialists," mainly in his right arm,
hand and fingers.
Dr. Katz concluded that (1) "[i]n [plaintiff's] case the long-term chronic
exposure to the chemical officially classified as highly toxic le[]d to the
development of slowly progressive long-term degenerative processes in the
peripheral nervous system manifesting as multifocal motor neuropathy of the
upper right extremity" and (2) there was a "confirmed loss of muscle bulk,
severe muscle weakness and inability [by plaintiff] to perform [the] simplest
A-3914-23 23 tasks such as closing fist and touching other fingers with thumb" in his right
hand.
Dr. Katz opined "[w]ithin [a] reasonable degree of medical certainty that
[plaintiff] is totally and permanently disabled for gainful employment as a direct
result of the exposure to the highly toxic chemical, methyl bromide." (Emphasis
added).
Dr. Laumbach's Occupational and Environmental Medicine Expert Report
In July 2022, Dr. Robert L. Laumbach issued an expert report. He is a
diplomate of the American Board of Preventive Medicine (Occupational
Medicine), the American Board of Family Medicine, the American Board of
Industrial Hygiene, and the American Board of Toxicology. He has over twenty-
five years of experience in the "analysis of the adverse health effects of
occupational and environmental agents, including chemical, physical, and
biological agents." Moreover, Dr. Laumbach is an M.D. and specializes in
Occupational and Environmental Medicine. He also has a Master's degree in
Public Health.
Dr. Laumbach was retained to address "whether or not [plaintiff] sustained
personal injuries due to exposure to methyl bromide . . . while employed at
A-3914-23 24 [PSA] as an expediter from about 2007 to 2017, and as a loader/expediter for
Del Monte from about 1998 to about 2007."
Dr. Laumbach's report reflects he interviewed and examined plaintiff on
February 11, 2022. He also considered a report from industrial hygienist Dr.
Richard M. Lynch (which we describe, infra), the depositions of plaintiff and
various employees from Gloucester and Western, and numerous medical
records.
From his physical examination of plaintiff, Dr. Laumbach found that he
had "[s]evere muscle wasting apparent in the right hand," right forearm, and to
a slight extent in his upper right arm. Plaintiff's grip was also significantly
weaker in his right hand compared to his left. Dr. Laumbach also noted that
plaintiff had reduced strength in his right hip.
Addressing the question of general causation, Dr. Laumbach's report
noted that methyl bromide is classified as a "[r]estricted [u]se [p]esticide" by
the EPA and that it is "a very toxic fumigant gas that has caused severe
poisonings and death." He stated that "[i]n case of overexposure to methyl
bromide, reports of neurological toxicity are common and associated with
characteristic findings on MRI of the brain consistent with central nervous
system ("CNS") toxicity, as well as peripheral neuropathy." His report detailed
A-3914-23 25 that exposure to methyl bromide "can cause gastrointestinal, neurological, and
respiratory injury" as well as "[h]eadaches, loss of appetite, nausea, vomiting,
visual disturbances, and fatigue and weakness," which "have been commonly
reported after short-term exposure to methyl bromide."
According to Dr. Laumbach, "[l]onger-term exposure is associated mainly
with neurological signs and symptoms in humans." Such exposure "has been
associated with a variety of central and peripheral nervous system disorders
including mental confusion, lethargy, loss of initiative, depressed libido,
personality changes, apathy, amnesia, aphasia, blurred vision, dysarthria,
polyneuropathy, and muscle weakness."
Dr. Laumbach stated that plaintiff's "neuropathy can be described as a
motor neuron neuropathy, mostly upper extremity, and mostly unilateral in the
right arm" and that plaintiff additionally exhibited "right lower extremity
weakness." He cited to several studies that have "noted that cases of acute and
chronic exposure [to methyl bromide] have included muscle weakness and pain"
as well as "upper and lower extremity weakness." He also noted that "[f]ew
studies have examined the effects of long-term exposure to methyl bromide on
exposed workers."
A-3914-23 26 Regarding specific causation, Dr. Laumbach found in his report that
plaintiff's "weakness, muscle wasting, cramping, and pain in the right forearm
and hand are typical of a motor neuron neuropathy" and that plaintiff "also had
symptoms of acute central nervous system toxicity." He noted plaintiff "had an
elevated bromide level in his blood . . . which documented substantial exposure."
Notably, "[a]fter [plaintiff] stopped working on the dock, his blood bromide
levels slowly declined as expected, to normal levels."
Dr. Laumbach found that the return to normal levels of bromide was
"consistent with cessation of exposure to methyl bromide after he stopped
working at the terminal in May of 2017." He also indicated that "occupational
exposure to methyl bromide has been associated with a variety of CNS and
peripheral nerve toxicities in exposed workers," and that "[t]he clinical
presentation of these exposed workers with methyl bromide poisoning have
included the signs and symptoms of [plaintiff's] disease."
Further, Dr. Laumbach determined that "[t]he elevated bromide level,
documenting substantial exposure to methyl bromide, and consistency and
specificity of [plaintiff's] clinical presentation with reported cases . . . provide
strong support for a causal association between occupational exposure to methyl
A-3914-23 27 bromide and [plaintiff's] peripheral neuropathy and central nervous system
symptoms." (Emphasis added).
Additionally, Dr. Laumbach found plaintiff's "acute symptoms" to be
"consistent with overexposure to methyl bromide" and that it was likewise
"highly likely that he had chronic overexposure to methyl bromide given the
conditions under which he worked." (Emphasis added).
In sum, Dr. Laumbach ultimately concluded that "[t]o a reasonable degree
of medical probability, all of [plaintiff's] peripheral and central nervous system
pathologies with onset at the time of, and in the several years preceding , the
discover[y] of his poisoning with methyl bromide, were caused by his
occupational exposure to methyl bromide while working as an expediter for PSA
and Del Monte." (Emphasis added).
Dr. Lynch's Industrial Hygienist Expert Report
In July 2022, plaintiff served an expert report from a third expert, Dr.
Lynch, who, while not a medical doctor, has a Ph.D. in public health and an
M.S. in industrial hygiene. Dr. Lynch visited the Gloucester terminal in June
2021, and inspected the cold storage boxes at Pier 8 and Pier 9.
Dr. Lynch's report expressed his opinion that plaintiff "was chronically
exposed to significant airborne levels of methyl bromide during his work tenure
A-3914-23 28 as [an] expediter at [Gloucester] over the course of his employment between
2006 and 2017."
Dr. Lynch's report detailed that the New Jersey Department of Health
("DOH") categorizes methyl bromide as a toxic substance and that it should be
"handle[d] . . . as a possible carcinogen." He noted that a DOH fact sheet from
2006 cautioned that "[r]epeated exposure may cause damage to the brain and
nervous system."
Along similar lines, Dr. Lynch's report also noted that the 2011 Material
Safety Data Sheet for methyl bromide indicated that "[l]ong term exposure may
cause peripheral nervous system disorders [and] central nervous system
disorders."
Dr. Lynch opined that any methyl bromide measurements from Western
in the cold storage boxes of Pier 8 and Pier 9 were "likely underestimates of
methyl bromide levels chronically experienced by [plaintiff] during the
approximate 11-year period." He stated plaintiff "was routinely exposed to
chronic airborne levels of methyl bromide at levels exceeding the American
Conference of Governmental Industrial Hygienists['] 8 hour threshold limit
value of 1 [ppm], as well as the Gloucester [t]erminal [BMT] guideline of 5
[ppm]." (Emphasis added).
A-3914-23 29 As to these measurements, Dr. Lynch opined "within a reasonable degree
of scientific certainty that airborne methyl bromide levels routinely exceeded 5
ppm to as high as 10 ppm" in the cold storage boxes, since methyl bromide likely
"continued to off-gas throughout the workday." (Emphasis added). Dr. Lynch
estimated that plaintiff's exposure "during the approximate 11 years of his
employment at Gloucester terminal conservatively ranged between 2 to 20
[ppm] for several hours of each typical workday within the cold box."
(Emphasis added).
Criticizing defendants' practice, Dr. Lynch stated that Gloucester and
Western knew that methyl bromide could off-gas and that they "failed to
exercise reasonable care to ensure that the off-gassing of methyl bromide did
not harm the workers." (Emphasis added). He also noted that Gloucester and
Western failed to follow their own FASSOP and BMP internal policies "to
ensure that workers . . . were not unreasonabl[y] exposed to excessive and unsafe
levels of methyl bromide."
Defendants' Expert Reports
Although we are obligated to review the summary judgment record and
expert reports in a light most favorable to plaintiff, we briefly describe the
competing expert reports tendered by defendants below.
A-3914-23 30 Dr. Thomas Lewandowski
Dr. Lewandowski has a Ph.D., in Environmental Health (Toxicology), a
Master's degree in Public Health, and has been the principal of an expert
consulting firm since 2001. His areas of expertise listed on his curriculum vitae
include product safety, risk assessment, chemical metabolism and disposition,
dermal toxicology, reproductive and developmental toxicology, and metals
technology. He issued an expert report for the defense in December 2022.
Based on his own analysis of the record, Dr. Lewandowski concluded , to
a reasonable degree of scientific certainty, "[t]here is no indication that during
the course of his employment at the Gloucester Terminal facility, [plaintiff] was
ever exposed to [methyl bromide] at concentrations above the OSHA
permissible exposure limit . . . of 20 ppm." (Emphasis added). He added that
"[a]ir monitoring data show[s] that any exposure was minimal and well below
the 20 ppm value." Dr. Lewandowski further opined that plaintiff's "claimed
long-term health effects . . . are not consistent with [methyl bromide] exposure
based on the available scientific evidence and are unlikely to have been caused
by [methyl bromide] exposure." (Emphasis added).
Dr. Lewandowski critiqued the analyses of two of plaintiff's three experts.
Among other things, he asserted that Dr. Laumbach relied on studies of
A-3914-23 31 incomparable "very high [methyl bromide] concentrations." He contended that
Dr. Katz's report citation of literature in the field is "limited" and "disregards
the important concept of dose."
In summary, Dr. Lewandowski concluded "there is no evidence that
[plaintiff] was ever exposed to [methyl bromide] levels above the OSHA
[permissible exposure level], or at a level sufficient to cause significant, chronic
injury." (Emphasis added).
Bernard Silverstein
Defense expert Bernard Silverstein, who we have mentioned, supra, has a
Master's degree in Environmental and Occupational Health Sciences, with a
concentration in Industrial Hygiene. Since he is not a medical doctor,
Silverstein did not address the question of medical causation. He issued a report
for defendants in this case in September 2022. He evaluated documents and data
for the time period from 2008-2017. His opinions were likewise issued to a
reasonable degree of scientific certainty.
Silverstein does not dispute the potential toxic effects of methyl bromide
exposure. He relied heavily on the 20 ppm ceiling limit set by OSHA to
conclude that there is no evidence to support the plaintiff's claims.
A-3914-23 32 He contends that plaintiff's expert Dr. Lynch relied on a misinterpretation
of the 5 ppm exposure limit, and, because there is no evidence that plaintiff was
ever exposed to levels above the 20 ppm ceiling established by OSHA, the safety
protocols in place were sufficient to protect the health of the employees.
Summary Judgment Practice
Gloucester moved for summary judgment seeking dismissal of plaintiff's
negligence claim, based largely on arguments about the preclusive effect of the
September 2004 general release. The trial court heard oral argument on the
motion on June 23, 2023, and issued an oral ruling that same day.
Based on what the court characterized as the "very conventional" language
of the general release between plaintiff and Gloucester, the court found that
"plaintiff can make a claim presumably for exposure to toxic chemicals but only
in regard to the exposure that occurred after the September of 2004 date in the
release."
Regarding causation, the court stated that plaintiff "need[ed] an expert to
say that the post September 2004 exposure in and of itself . . . to a reasonable
degree of medical probability . . . was enough to probably cause" plaintiff's
injuries. (Emphasis added). "[A]bsent that," the court did not "think you get to
the jury and [get to] ask the jury [to] speculate that whatever exposure the
A-3914-23 33 plaintiff had to those chemicals after September 20[0]4 in and of itself was
sufficient to cause their problems." (Emphasis added).
The court reviewed the reports of Drs. Lynch and Laumbach, but did not
"see anything that basically said that [post-2004 exposure to methyl bromide]
alone could have caused" plaintiff's injuries. Acknowledging that Gloucester
did not have Western begin air sampling for methyl bromide in the cold storage
boxes until around 2011 or 2012, the court did not "read from what [plaintiff]
just provided . . . anything that says that . . . exposures during the hard number
periods," referring to 2011 and beyond when air sampling was conducted in the
cold storage boxes, "alone can cause the problems." (Emphasis added). The
court added that "any exposure after 20[0]4 was inconsequential because the
damage is already done."
Since the court deemed plaintiff to bear the burden to prove causation, the
court concluded "that gap in knowledge concerning hard numbers [of methyl
bromide levels in the cold storage boxes] that predated 2012, the consequences
of that gap, are not going to be visited upon Gloucester Terminals." Because
plaintiff could not "prove whether or not it was the exposure that predated 2004
as opposed to the exposure that postdated 2004" that caused his injuries, the
A-3914-23 34 court granted Gloucester's motion for summary judgment as to plaintiff's
negligence claim and entered an order to that effect on June 23, 2023.
Plaintiff moved for reconsideration of the order granting summary
judgment to Gloucester. Meanwhile, Western filed its own motion for summary
judgment on plaintiff's negligence claim on a similar basis as Gloucester had
regarding causation, namely that plaintiff's experts were unable to opine that his
methyl bromide exposure while working exclusively for PSA from 2007
onwards was the cause of plaintiff's injuries.
The trial court held oral argument on both motions on September 8, 2023.
The court observed that if it denied the motion for reconsideration granting
summary judgment to Gloucester, it "almost certainly [would be] granting the
motion for summary judgment" in favor of Western "because . . . they contain
either identical or substantially similar arguments."
The court denied the motion for reconsideration because "none of the
plaintiff's experts even attempted to indicate that exposure post-release was a
substantial factor" in causing plaintiff's injuries, and plaintiff therefore could
not meet the standard for proximate causation to satisfy their negligence claim.
That same day, September 8, 2023, the court entered an order denying
plaintiff's motion to reconsider the grant of summary judgment to Gloucester.
A-3914-23 35 The court similarly granted Western's motion for summary judgment largely for
the same reasons. The court entered an order dismissing all claims against
Western on September 11, 2023.
Punitive Damages Rulings
Apart from these liability issues, each defendant also moved for dismissal
of plaintiff's claims for punitive damages under N.J.S.A. 2A:15-5.9 to -5.17, in
the hypothetical event that liability was established. Western filed its motion
first, styled as a motion for partial summary judgment.
On July 6, 2023, the court orally granted Western's motion. For reasons
we will explore, infra, in Part II(D), the court concluded that plaintiff could not
show, by clear and convincing proof, that Western had a "wanton and willful
disregard" of plaintiff's health stemming from his workplace exposure to methyl
bromide. Although the court acknowledged that Western did not begin sampling
for methyl bromide in the cold storage boxes until 2012, the court did not regard
Western's conduct to qualify as "especially egregious" to warrant punitive
damages. The court issued a written order on the same day memorializing that
determination.
Gloucester similarly moved for partial summary judgment dismissing the
punitive damages claims against it. By the time the court considered that
A-3914-23 36 motion, it had already granted Gloucester summary judgment on liability as to
plaintiff's underlying negligence claims. Consequently, the court deemed
Gloucester's punitive damages dismissal motion moot, issuing an order to that
effect on July 21, 2023.
This appeal by plaintiff followed.
II.
On appeal, plaintiff argues the trial court erred in granting summary
judgment to both defendants. Fundamentally, he contends that the court failed
to apply New Jersey's more lenient standards for proving medical causation in a
toxic-tort workplace exposure case. Plaintiff further argues the court improperly
found deficient the opinions of his experts in not explicitly segregating the harm
to plaintiff from his exposure to methyl bromide at the Delaware terminal while
he worked there previously for Del Monte.
Plaintiff similarly asserts that the court erred in faulting his experts for
not segregating the exposures that occurred, respectively, before his September
2004 release with Gloucester and, as to Western, the exposures that occurred
before Western began fumigating at the Gloucester Terminal in or about 2007.
A-3914-23 37 Additionally, plaintiff argues the trial court erred as a matter of law in too
broadly construing the 2004 general release. Lastly, he argues that the court
should have preserved his claims for punitive damages against both defendants.
A.
We address plaintiff's' arguments utilizing familiar standards of summary
judgment and appellate review. Appellate courts review a grant of summary
judgment de novo, applying the same standard as the motion judge. Samolyk v.
Berthe, 251 N.J. 73, 78 (2022). That standard requires a determination be made
as to "whether 'the pleadings, depositions, answers to interrogatories and
admissions on file, together with the affidavits, if any, show that there is no
genuine issue as to any material fact challenged and that the moving party is
entitled to a judgment or order as a matter of law.'" Branch v. Cream-O-Land
Dairy, 244 N.J. 567, 582 (2021) (quoting R. 4:46-2(c)).
"To decide whether a genuine issue of material fact exists, the trial court
must 'draw[] all legitimate inferences from the facts in favor of the non-moving
party.'" Friedman v. Martinez, 242 N.J. 449, 472 (2020) (alteration in original)
(quoting Globe Motor Co. v. Igdalev, 225 N.J. 469, 480 (2016)). "An issue of
fact is genuine only if . . . the evidence submitted by the parties on the motion,
together with all legitimate interferences therefrom favoring the non -moving
A-3914-23 38 party, would require submission of the issue to the trier of fact." R. 4:46-2(c).
By comparison, "[t]o the extent that the grant or denial of summary judgment is
based on an issue of law, [appellate courts] owe no deference to an interpretation
of law that flows from established facts." State v. Perini Corp., 221 N.J. 412,
425 (2015) (citing Town of Kearney v. Brandt, 214 N.J. 76, 92 (2013)).
B.
As a threshold issue that only concerns defendant Gloucester, we address
the trial court's interpretation of the September 14, 2004 general release that
plaintiff provided to Gloucester when he settled his federal case arising from his
workplace Achilles heel injury.
The release stated, in pertinent part, as follows:
[Plaintiff] release[s] any and all rights which [Plaintiff] may have against [Gloucester]. This releases all claims, including those of which [plaintiff is] not aware and those not identified in this [r]elease. This [r]elease applies to claims resulting from anything which has occurred to date. [Plaintiff] specifically release[s] the following claims:
a. Any and all past, present or future claims . . . of any nature whatsoever based upon a tort, contract or other theory of recovery and whether for compensation or punitive damages [plaintiff] now ha[s], or which may hereafter accrue or otherwise be acquired, against [Gloucester] either directly or indirectly, including by way of example and not limitation, those which may or could have been the subject matter of [the] lawsuit
A-3914-23 39 instituted in the United States District Court for the District of New Jersey, Civil Action No.: 03-3530.
b. This [r]elease is for compensation of any and all injuries [plaintiff] sustained, known, unknown or unknowable. . . . It is expressly understood that this [r]elease is for the settlement, release, discharge and elimination of any and all claims. [Plaintiff] hereby acknowledge[s] that by executing this [r]elease and accepting the monies paid hereunder, [plaintiff] and those who otherwise might be entitled to make such a claim or claims in the future have received fair, just and adequate compensation for all such claims in exchange for which all such claims, past, present and future are forever released and discharged. . . . Even if additional facts become known which were not known at this time this [r]elease was executed, [plaintiff] waive[s] [his] right to bring a lawsuit against [Gloucester].
Plaintiff argues the release does not limit his claims against Gloucester to
any extent because this case is about his workplace exposure to methyl bromide
and has nothing to do with his Achilles heel injury. The trial court appropriately
rejected that no-limitation argument.
A general release is "merely a form of contract and the general rules that
apply to contract interpretation apply to releases." Domanske v. Rapid-Am.
Corp., 330 N.J. Super. 241, 246 (App. Div. 2000). The interpretation of the
release is therefore subject to de novo review by an appellate court, which will
"pay no special deference to the trial court's interpretation and look at the
contract with fresh eyes." Kieffer v. Best Buy, 205 N.J. 213, 223 (2011).
A-3914-23 40 Certain well-established principles apply to this issue. "A basic principle
of contract interpretation is to read the document as a whole in a fair and
common sense manner." Hardy ex rel. Dowdell v. Abdul-Matin, 198 N.J. 95,
103 (2009). "If the terms of a contract are clear, they are to be enforced as
written." Malick v. Seaview Lincoln Mercury, 398 N.J. Super. 182, 187 (App.
Div. 2008). Likewise, "[t]he scope of a release is determined by the intention
of the parties as expressed in the terms of the particular instrument, considered
in the light of all the facts and circumstances." Bilotti v. Accurate Forming
Corp., 39 N.J. 184, 203-04 (1963).
"A general release, not restricted by its terms to particular claims or
demands, ordinarily covers all claims and demands due at the time of its
execution and within the contemplation of the parties." Id. at 204. When a
release's language refers to "any and all" claims, courts generally do not permit
exceptions. Isetts v. Borough of Roseland, 364 N.J. Super. 247, 255-56 (App.
Div. 2003).
Plaintiff argues the trial court erred in "barr[ing]" him "from asserting an
occupational-exposure, toxic tort claim not known until May of 2017." But the
trial court did not find that the release barred plaintiff from asserting his current
claim in its entirety. The court instead found that the general release precluded
A-3914-23 41 plaintiff from bringing his claim against Gloucester in relation to any methyl
bromide exposure that occurred before the September 14, 2004 release. That
interpretation of the release was sound.
The plain language of the release refutes plaintiff's argument. Malick, 398
N.J. Super. at 187. The release, which plaintiff entered into with the advice of
counsel, states that it applies to claims "resulting from anything which has
occurred to date," and specifies that would include "[a]ny and all past, present
or future claims . . . of any nature whatsoever" "known, unknown or
unknowable." It similarly states that "[e]ven if additional facts become known
which were not known at this time this [r]elease was executed," plaintiff still
"waive[s] [his] right to bring a lawsuit against" Gloucester.
It is therefore clear from the plain language of the release, as the trial court
found, that the "intention of the parties" was that plaintiff released all claims
against Gloucester of any kind that occurred up to September 14, 2004–whether
related or unrelated to his Achilles injury and whether plaintiff knew about them
or not–which would include his current claims for pre-September 2004 toxic
exposure to methyl bromide. Bilotti, 39 N.J. at 203. The release does not
"restrict[] by its terms" that it only applies to "particular claims or demands"
A-3914-23 42 arising from the Achilles injury, and it therefore "covers all claims and demands
due at the time of its execution. . ." Id. at 204.
Plaintiff relies on Isetts, 364 N.J. Super. at 251-55, for his assertion that
he only released claims related to his Achilles injury. In Isetts, the plaintiff first
filed suit against his employer in January 2000 alleging he was subject to
harassment and retaliation. 364 N.J. Super. at 250. The case was settled in
2001, and the plaintiff signed a general release releasing his employer from "all
claims resulting from anything that has happened up to the date of its execution"
including all claims "that were asserted or could have been asserted." Id. at 251.
After the execution of the release, the plaintiff in Isetts was subject to new
incidents of harassment and retaliation and subsequently filed a second suit.
Ibid. The court explained that the plaintiff "acknowledge[d] that all claims
existing at the time of the settlement ha[d] been extinguished by way of the
release." Id. at 254. The court also recognized that the phrase "any and all
claims, rights, actions and causes of action of any kind" in the general release
"allows for no exception" and that the plaintiff had "surrendered 'any and all' of
his existing 'claims, rights, actions and causes of action.'" Id. at 255-56. The
only question in Isetts was whether that language would similarly bar the
plaintiff from the right to seek discovery in the later unreleased action. Id. at
A-3914-23 43 256. Hence, Isetts is distinguishable as a case about discovery, not about the
disposition of the legal effect of a general release.
We therefore affirm the court's ruling concerning the release in the present
case. Plaintiff's' claims against Gloucester are limited to recovery for harms
caused by methyl bromide exposure after September 14, 2004. 10
C.
We turn to the central issues of medical causation affecting both
defendants, which are at the heart of this appeal. We preface that discussion
with some important background about New Jersey's distinctive approach to
medical causation questions in toxic-tort and occupational exposure cases.
New Jersey's "Substantial Factor" Test of Causation for Toxic-Tort Cases
Generally speaking, to establish a claim for negligence, a plaintiff must
prove (1) a duty of care; (2) a breach of that duty; (3) proximate causation; and
(4) injury. Stevens v. N.J. Transit Rail Operations, 356 N.J. Super. 311, 318-19
(App. Div. 2003). The third element—causation—is pivotal to the liability
issues on this appeal.
10 We discuss, infra at Part II(C), the burdens of proof associated with that temporal limitation. A-3914-23 44 Our courts have prescribed special rules for establishing causation in toxic
tort lawsuits in this state. "[T]he modern trend has been to relax or broaden the
standard for determining medical causation in toxic-tort litigation." James v.
Chevron U.S.A., Inc., 301 N.J. Super. 512, 530 (App. Div. 1997). This is
because "[i]n the toxic-tort context, 'proof that a defendant's conduct caused [a
plaintiff's] injuries is more subtle and sophisticated than proof in cases
concerned with more traditional torts.'" Id. at 531 (quoting Landrigan v. Celotex
Corp., 127 N.J. 404, 413 (1992)).
As our Supreme Court has instructed, "[i]n a toxic tort action," including
in cases such as this involving occupational exposure to toxic materials, "a
plaintiff must prove what is known as 'medical causation'—that the plaintiff's
injuries were proximately caused by exposure to the defendant's product."
James v. Bessemer Processing Co., Inc., 155 N.J. 279, 299 (1998).
"To prove medical causation, a plaintiff must show 'that the exposure
[from the defendant's product] was a substantial factor in causing or
exacerbating the disease.'" Ibid. (quoting Sholtis v. Am. Cyanamid Co., 238
N.J. Super. 8, 30-31 (App. Div. 1989)) (emphasis added).
Conduct is a "substantial factor" if it would:
[L]ead the trier of fact, as a reasonable person, to regard it as a cause, using that word in the popular sense.
A-3914-23 45 Under the "substantial factor" test, the defendant's negligence need not be the sole or primary factor producing the injury; it need only be a substantial factor. Thus the test covers the situation where there may be several substantial factors contributing to the same result.
[Verdicchio v. Ricca, 179 N.J. 1, 24-25 (2004) (quoting J.D. Lee & Barry A. Lindahl, Modern Tort Law: Liability & Litigation § 4.03, 4-4 (West Group 2002)) (emphasis added).]
That said, "merely establishing that a defendant's negligent conduct had
some effect in producing the harm does not automatically satisfy the burden of
proving it was a substantial factor . . ." Id. at 25 (emphasis added). As the Court
elaborated in Verdicchio:
Some other event which is a contributing factor in producing the harm may have such a predominant effect in bringing it about as to make the effect of the actor's negligence insignificant and, therefore, to prevent it from being a substantial factor. So too, although no one of the contributing factors may have such a predominant effect, their combined effect may, as it were, so dilute the effects of the actor's negligence as to prevent it from being a substantial factor.
[Ibid. (quoting Restatement (Second) of Torts § 433 cmt. d (Am. L. Inst. 1965)).]
Hence, "a defendant's deviation need not be the only cause, nor primary
cause, for the deviation to be a substantial factor in producing the ultimate
result" but "defendant's negligent conduct cannot be a remote or inconsequential
A-3914-23 46 contributing factor." Id. at 30 (emphasis added). "It must play a role that is both
relevant and significant in bringing about the ultimate injury." Ibid.
This approach is consistent with the instructions to Model Jury Charge s
(Civil), 6.12, "Proximate Cause — Where There Is Claim That Concurrent
Causes Of Harm Were Present" (Nov. 2023), which advises:
In toxic tort (i.e. asbestos exposure) cases where the plaintiff has presented competent and credible evidence that even a minimal exposure to the substance can cause the claimed injury or disease, it may be appropriate for the court to instruct the jury that a substantial factor is an 'efficient cause' of the claimed injury or disease and not a remote or trivial cause having only an insignificant connection with the harm, but that liability should not attach based on casual or minimal contact with the product or imposed based on mere guesswork.
See also Fowler v. Akzo Nobel Chemicals, Inc., 251 N.J. 300 (2022).
Frequency, Regularity and Proximity
In Sholtis, a case involving the plaintiffs' exposure over a long period of
time to multiple asbestos products manufactured by multiple defendants, we
held that:
If the evidence establishes that reasonable jurors could infer that sometime during their work histories . . . plaintiffs were exposed to a defendant's friable asbestos frequently and on a regular basis, while they were in close proximity to it (balancing these factors); and if competent evidence, usually supplied by expert proof, establishes a nexus between the exposure and plaintiff's
A-3914-23 47 condition, then that defendant's summary judgment motion must be denied.
[238 N.J. Super. at 31 (emphasis added).]
We noted in Sholtis this test "appears to us to be well-reasoned, properly
focusing upon the cumulative effects of the exposure" and that "[i]t is a fair
balance between the needs of plaintiffs (recognizing the difficulty of proving
contact) and defendants (protecting against liability predicated on guesswork )."
Id. at 29.
As to the allocation of liability in such matters, we further explained in
Sholtis that, if a fact-finder found that one or all of the defendants were at fault,
"any proof allowing a reduction from joint and several responsibility would
come from these defendants' (not plaintiffs') urging that their respective shares
should be reduced under the principles of comparative negligence." Id. at 30.
In that sense, "[d]efendants would merely be joint tortfeasors, seeking . . . to
reduce their culpability based upon . . . a smaller share of plaintiffs' total
exposure." Ibid.
Our Supreme Court has rejected the notion that the Sholtis test should only
be used in cases involving asbestos exposure. It held in James that the Sholtis
test could be used generally in occupational exposure, toxic-tort cases to
establish medical causation. James, 155 N.J. at 304. The Court "stress[ed]" that
A-3914-23 48 "[t]he 'frequency, regularity and proximity' test [of medical causation] assigns
liability only to those defendants to whose products the plaintiff can demonstrate
he or she was intensely exposed," and "bears no relationship to theories of
collective liability that some courts have adopted in contexts where the specific
tortfeasor or tortfeasors that caused plaintiff's injury cannot be identified." Id.
at 302.
More recently, the Court has made clear that "the Sholtis test is adaptable
to varying scenarios and should not be rigidly and inflexibly applied." Fowler
v. Akzo Nobel Chems., Inc., 251 N.J. 300, 334 (2022). "The frequency,
regularity, and proximity test is merely an articulation of what constitutes a
substantial factor for purposes of determining proximate cause in an
occupational exposure setting." Id. at 336.
Applying the Causation Tests to this Case
As we noted above, in granting summary judgment to Gloucester on
plaintiff's post-release negligence claims, the trial court found that plaintiffs had
failed to sustain what the court perceived as their burden to show that the
exposure from the post-2004 time period "alone" caused damage. The court also
criticized plaintiffs for being unable to "prove whether or not it was the exposure
A-3914-23 49 that predated 2004 as opposed to the exposure that postdated 2004." (Emphasis
Having framed the test in this "either-or" manner, the trial court did not
sufficiently appreciate whether genuine issues of material fact existed
concerning whether plaintiff's post-release exposure at Gloucester could at least
be a "substantial factor" in causing his symptoms. In fact, the court made its
own pre-emptive determination that the damage had "already [been] done."
The court did not make any findings about the frequency, regularity, and
proximity of plaintiff's post-September 2004 exposure at Gloucester.
Later, in granting summary judgment to Western, the court used different
terminology in its oral opinion but reached the same conclusion. This time, the
court found that plaintiff's "experts have not indicated at all that exposure . . . to
the time period where [Western] will be responsible for the methyl bromide was
a substantial factor" in causing plaintiff's injuries, resulting in the court
"granting their motion" for summary judgment also. (Emphasis added).
However, despite using that terminology, the court did not explain why that
exposure for a decade (from about 2007 when plaintiff began working at the
terminal where Western performed fumigation to plaintiff's resignation in 2017)
A-3914-23 50 was merely insubstantial. Nor did the court address as to Western the frequency,
regularity, and proximity factors as prescribed by case law.
The trial court's series of oral opinions did not discuss, nor did they cite
to, the precedents in James, Verdicchio, or Fowler. The motion transcripts
reflect the court only briefly alluded to Sholtis without discussing that case in
depth. The court's rulings do not reflect a sufficient recognition that "[i]n [the]
toxic-tort context, 'proof that a defendant's conduct caused a [plaintiff's] injuries
is more subtle and sophisticated than proof in cases concerned with more
traditional torts.'" James, 155 N.J. at 299 (quoting Landrigan, 127 N.J. at 413).
Plaintiff does not have to show that the sole, or even primary, factor in
causing his injuries was his post-2004 methyl bromide exposure to survive
summary judgment against Gloucester; he must only make out a prima facie case
that the post-2004 exposure was a substantial factor in causing his injuries. Ibid.
We repeat that our courts have stated that a substantial factor "'need not be the
sole or primary factor producing the injury'" and that the substantial factor test
"'covers the situation'" as here "'where there may be several substantial factors
contributing to the same result.'" Verdicchio, 179 N.J. at 24-25 (quoting J.D.
Lee & Barry A. Lindahl, Modern Tort Law: Liability & Litigation § 4.03, 4-4
(West Group 2002)). Thus, even if plaintiff's pre-September 2004 exposure was
A-3914-23 51 a substantial factor in causing his injuries, that does not preclude that his post -
September 2004 exposure could also be a substantial factor in causing his
injuries, which the trial court failed to acknowledge or address.
Gloucester argues the Sholtis standard does not apply here because this
case involves a single toxic product. It is true that this case is not wholly
analogous to many of the occupational toxic-tort cases utilizing Sholtis that have
involved multiple toxic products and multiple defendants. However, as we
noted above, our Supreme Court has clarified that the Sholtis test is "adaptable
to varying scenarios and should not be rigidly and inflexibly applied." Fowler,
251 N.J. at 334.
Furthermore, the Sholtis test is just "an articulation of what constitutes a
substantial factor for purposes of determining proximate cause in an
occupational exposure setting." Id. at 336. Thus, while the facts are not
identical to those in several of the cases applying Sholtis, the concept behind
Sholtis is applicable here, since there are multiple players in this case, including
Gloucester, Western, and Del Monte–all of whom were involved in exposing
plaintiff to methyl bromide over the course of his career, the cumulative
exposure of which plaintiff asserts caused his injuries. The factual record
reasonably supports that plaintiff's exposure to the toxic chemical during his
A-3914-23 52 release-eligible years at Gloucester Terminal was (1) frequent, (2) regular, and
(3) in close proximity to the cold storage area where the gas was emitted. See
Sholtis, 238 N.J. Super. at 31.
The fact that Dr. Laumbach in his expert report attested to causation
caused by plaintiff's occupational exposure "while working as an expediter for
PSA and Del Monte" does not mean that plaintiff's exposure at PSA was
inconsequential. (Emphasis added).
Dr. Lynch's report, meanwhile, temporally addressed plaintiff's chronic
exposure to methyl bromide during his work tenure at the Gloucester terminal
"between 2006 and 2017." Dr. Lynch notably "estimate[d] that [plaintiff's]
exposure during the approximate 11 years of his employment at Gloucester
terminal conservatively ranged between 2 to 20 [ppm] for several hours of each
typical workday within the cold box" due to off-gassing from the fumigation
during the 2006 to 2017 timeframe. Thus, Dr. Lynch's expert report
substantiates that plaintiff was in frequent, regular, and close proximity with
methyl bromide while working at the Gloucester terminal post-2004. See
Viewing the record in the light most favorable to plaintiff, his experts can
establish in relation to Gloucester that his post-2004 exposure was a substantial
A-3914-23 53 factor in causing or exacerbating his medical symptoms. See James, 155 N.J. at
299.
Dr. Laumbach's report attested that even short-term exposure to methyl
bromide could cause "[h]eadaches, loss of appetite, nausea, vomiting, visual
disturbances, and fatigue and weakness," symptoms which plaintiff experienced.
More importantly, Dr. Laumbach stated that longer-term exposure to methyl
bromide could cause "neurological signs and symptoms in humans" and "has
been associated with a variety of central and peripheral nervous system disorders
including mental confusion, lethargy, loss of initiative, depressed libido,
personality changes, apathy, amnesia, aphasia, blurred vision, dysarthria,
polyneuropathy, and muscle weakness." Plaintiff's deposition provided
abundant evidence of these multiple severe injuries.
Both Drs. Katz and Laumbach's respective reports concluded that
plaintiff's injuries were consistent with long-term exposure to methyl bromide.
Dr. Katz concluded that plaintiff's long-term exposure to methyl bromide had
"le[]d to the development of slowly progressive long-term degenerative
processes in the peripheral nervous system" that particularly manifested in
muscle weakness in plaintiff's right fingers, hand, and arm. Dr. Laumbach
similarly concluded there was "strong support for a causal association between
A-3914-23 54 occupational exposure to methyl bromide and [plaintiff's] peripheral neuropathy
and central nervous system symptoms."
Thus, plaintiff's' experts emphatically opined that he had injuries
consistent with long-term exposure to methyl bromide. Even if his short-term
symptoms such as headaches and nausea were caused by methyl bromide
exposure before 2004, which Gloucester cannot be liable for, his long-term
exposure to methyl bromide from 2004 until 2017 at the Gloucester terminal
was also a factor in "exacerbating" plaintiff's injuries, resulting in his right hand
and arm degeneration and central nervous system issues. See James, 155 N.J.
at 299. The record likewise supports an inference that plaintiff's exposure for
about a decade from 2007 to 2017 when Western was the fumigator on site could
be regarded as a substantial factor in producing his medical symptoms.
In sum, viewing the summary judgment record de novo, in a light most
favorable to plaintiff, we conclude there are genuine and material facts presented
by his three experts' reports to create jury questions of medical causation. Even
if one were to confine Gloucester's potential causation role to the period from
September 2004 to May 2017, and to confine Western's role from approximately
A-3914-23 55 2007 to May 2017, the reports of plaintiff's experts11 collectively provide
sufficient evidence for a jury to assess the substantiality of each defendant 's'
contribution to the harm.
Burdens of Proof and Allocation of Responsibility
This brings us to a discussion of burdens of proof and the potential
allocation of responsibility. Given that, as we ruled in Part II(B), the general
release limits Gloucester's potential liability to claims arising after September
2004, Gloucester argues that plaintiffs bear the burden of proving the extent of
the harms caused after that date. In fact, the burden rests on Gloucester, for two
reasons.
First, Gloucester has invoked the release as an affirmative defense limiting
its liability. As a matter of black-letter law, defendants commonly have the
burden of proving the merits of the affirmative defenses they assert. See, e.g.,
Roberts v. Rich Foods, Inc., 139 N.J. 365, 378 (1995) (alteration in original)
("'When an affirmative defense is raised [in a civil case], the defendant normally
has the burden of proving it'"); Vill. of Ridgefield Park v. N.Y., Susquehanna
and W. Ry. Corp., 318 N.J. Super. 385, 395 (App. Div. 1999) ("A defendant
11 We do not foreclose defendants from moving in limine to bar or limit the admissibility of any of plaintiff's experts' testimony on net opinion or other grounds. A-3914-23 56 relying on an affirmative defense has the burden of persuasion by a
preponderance of the evidence").
Second, as we noted above, toxic-tort case law in our state, upon the
presentation of a prima facie case of causation, shifts the burden "to the culpable
defendant who should be held responsible for all damages unless he can
demonstrate that the damages for which he is responsible are capable of some
reasonable apportionment and what those damages are." Sholtis, 238 N.J. Super.
at 28 (quoting Fosgate v. Corona, 66 N.J. 268, 272-73 (1974)). This principle
applies to both Gloucester and Western. It imposes a burden on each of them,
if they seek a reduction of damages for exposures that occurred during earlier
time frames or caused by a different actor, to prove they are entitled to such a
"reasonable apportionment," as well as the extent of any such apportionment.
The apportionment could also address comparative differences in the respective
roles of Gloucester and Western vis-à-vis one another.
To carry out this burden-shifting principle, the trial court may consider
crafting case-specific jury instructions, along with special interrogatories on the
verdict form, that would assist a jury in making a fair allocation or reduction of
damages from exposures that preceded Gloucester's September 2004 release and
Western's approximate involvement at plaintiff's workplace starting in or about
A-3914-23 57 2007. We leave it to the discretion of the trial court in fashioning such
appropriate jury charges and a tailored verdict form with the input of trial
counsel.
The Non-Dispositive Relevance of the OSHA 20 ppm Standard to Ordinary Negligence
Defendants urge they cannot be found liable for negligence because there
is no proof that the exposure levels at the terminal while plaintiff was working
there ever exceeded the EPA standard of 20 ppm, as set forth in 29 C.F.R. §
1910.1000(a) (denoted as "Table Z-1"). That data is not, however, dispositive
of reasonable care, for reasons elaborated by plaintiff's' scientific experts. For
one thing, testing protocols were not instituted until 2012, many years after
plaintiff began working there and was exposed to off-gas discharges. In
addition, the areas where plaintiff worked were generally not tested in the
afternoons, even though testimony showed that off-gassing can continue for up
to seventy-two hours after the fruit is treated. Also, the testing data sometimes,
albeit not frequently, produced levels above the 5 ppm mark established under
the FASSOP in 2012. Plaintiff's' experts further identified other government or
industry standards more stringent than the OSHA 20 ppm, or those pertaining to
average all-day exposures rather than episodic peaks.
A-3914-23 58 Most importantly, the OSHA 20 ppm level, while surely relevant and
admissible evidence at trial, does not dictate civil liability for ordinary
negligence. See Costantino v. Ventriglia, 324 N.J. Super. 437, 444 (App. Div.
1999) (noting an "OSHA regulation was an available but not a required standard
of care against which to measure defendants' conduct"). Depending on the
proofs adduced, a jury would be free to conclude a company's behavior in
safeguarding its employees from toxic methyl bromide exposure was
unreasonable despite the company's compliance with the OSHA 20 ppm
standard.12
Conclusion Regarding Causation Issues and Summary Judgment
For these multiple reasons, the trial court erred in granting summary
judgment to Gloucester and Western. As we have shown, the court failed to
conduct a fulsome analysis of the less stringent causation standards that govern
toxic-tort occupational exposure cases in New Jersey. The court also did not
consider plaintiff's expert reports in a light most favorable to them as the non-
moving parties. Summary judgment on liability is consequently reversed.
12 But see our discussion in Part II(D), infra, concerning punitive damages. A-3914-23 59 D.
Finally, we consider the motions of Western and Gloucester for partial
summary judgment dismissing plaintiff's demands for punitive damages.
Although the court granted Western's motion but denied as moot Gloucester's
motion, we consider both motions together, discerning no need for a remand as
to Gloucester since the analysis substantially is the same.
The Punitive Damages Act ("PDA"), N.J.S.A. 2A:15-5.9 to -5.17, was
enacted "to establish more restrictive standards with regard to the awarding of
punitive damages." Pavlova v. Mint Mgmt. Corp., 375 N.J. Super. 397, 403
(App. Div. 2005). The PDA "requires an award of compensatory damages as a
statutory precedent for an award of punitive damages. . ." Ibid.; N.J.S.A. 2A:15-
5.13(c). In most respects, the PDA "codified the common law . . . which limited
punitive damages to only 'exceptional cases . . . as a punishment of the defendant
and as a deterrent to others from following his [or her] example.'" Pavlova, 375
N.J. Super. at 404 (quoting Di Giovanni v. Pessel, 55 N.J. 188, 190 (1970)).
To justify the imposition of punitive damages, N.J.S.A. 2A:15-5.12(a)
instructs that:
Punitive damages may be awarded to the plaintiff only if the plaintiff proves, by clear and convincing evidence, that the harm suffered was the result of the defendant's acts or omissions, and such acts or
A-3914-23 60 omissions were actuated by actual malice or accompanied by a wanton and willful disregard of persons who foreseeably might be harmed by those acts or omissions. This burden of proof may not be satisfied by proof of any degree of negligence including gross negligence.
[(Emphasis added).]
See also Nappe v. Anschelewitz, Barr, Ansell & Bonello, 97 N.J. 37, 49 (1984)
(same).
Wanton and willful disregard is defined in the PDA as "a deliberate act or
omission with knowledge of a high degree of probability of harm to another and
reckless indifference to the consequences of such act or omission." N.J.S.A.
2A:15-5.10. The PDA provides a non-exclusive list of factors the factfinder
must consider in determining whether to award punitive damages, including:
(1) The likelihood, at the relevant time, that serious harm would arise from the defendant's conduct;
(2) The defendant's awareness or reckless disregard of the likelihood that the serious harm at issue would arise from the defendant's conduct;
(3) The conduct of the defendant upon learning that its initial conduct would likely cause harm; and
(4) The duration of the conduct or any concealment of it by the defendant.
[N.J.S.A. 2A:15-5.12(b).]
A-3914-23 61 "Case law considers these same types of factors." Pavlova, 375 N.J. Super. at
404.
"[M]ere negligence, however gross, is not enough" but "the standard
signifies something less than an intention to hurt." Id. at 405. "[T]he standard
can only be established if the defendant knew or had reason to know of
circumstances which would bring home to the ordinary reasonable person the
highly dangerous character of his or her conduct." Ibid. To that end, a plaintiff
"may not recover punitive damages by 'recasting merely negligent conduct as
"willful and wanton."'" Edwards v. Our Lady of Lourdes Hosp., 217 N.J. Super.
448, 460 (App. Div. 1987) (quoting Entwistle v. Draves, 102 N.J. 559, 562
(1986)).
Here, we conclude that, even affording plaintiff all reasonable inferences,
there is nothing in the record to support his claim that Western's conduct rose to
the level of "wanton and willful disregard" to warrant punitive damages.
N.J.S.A. 2A:15-5.12(a). Plaintiff argues that Western acted with wanton and
willful disregard for his safety to warrant punitive damages because it knew
methyl bromide could off-gas, but Western generally only took one air sample
for it in the morning in the cold storage boxes at Pier 8 and Pier 9 and generally
A-3914-23 62 not in the afternoon. Plaintiff contends Western should have conducted
"additional testing throughout the day" and that its failure to do so was reckless.
As we noted above, this conduct does not rise to the level of wanton and
willful disregard to warrant punitive damages. The record shows that various
Gloucester and Western employees did know that methyl bromide could off-gas.
Moreover, Quigley, Gloucester's former director of safety and loss control,
stated that once he joined the task force regarding how methyl bromide was
being handled around 2011 and learned that methyl bromide could off-gas,
Gloucester began air sampling for methyl bromide in the cold storage boxes of
Pier 8 and Pier 9, rather than only sampling in the sheds where the actual
fumigation occurred.
Based on that information, Western, in conjunction with Gloucester,
developed the FASSOP for air sampling for methyl bromide in the cold storage
boxes, and set limits for how much methyl bromide would be permissible. Those
limits included Western notifying Gloucester if the methyl bromide reading in
the cold storage box was above 5 ppm and restricting access to the cold storage
boxes if the methyl bromide reading was above 10 ppm. As part of the FASSOP,
Western would sample the air for methyl bromide in the cold storage boxes in
the morning "prior to anyone entering" the cold storage boxes for work.
A-3914-23 63 As the trial court found, there is nothing "wanton" or "reckless" inherent
to that procedure. No Western or Gloucester employee who was deposed
testified that they actively ignored the 5 or 10 ppm thresholds contained in their
joint BMP and FASSOP for methyl bromide sampling in the cold storage boxes.
Moreover, as we noted above, OSHA's permissible exposure limit is 20
ppm, 29 C.F.R. § 1910.1000, and Reichert, Western's fumigation director,
confirmed that the five and ten ppm thresholds were site-specific to Gloucester.
Silverstein, Western's industrial hygienist, stated that he reviewed the logs and
concluded that "none of the sampling data reviewed indicated any exposures
above the OSHA standard of 20 ppm which is the exposure limit for workers
like [plaintiff]." Plaintiff does not argue that he was ever exposed to methyl
bromide levels greater than OSHA's permissible exposure limit of 20 ppm and
conceded in his appellate brief that the methyl bromide samples in the logs from
the cold storage boxes "do not exceed OSHA permissible levels."
Overall, because plaintiff cannot show that Western acted with either
actual malice or wanton and willful disregard to his safety through its cold
storage box sampling procedures, punitive damages are not warranted. N.J.S.A.
2A:15-5.12(a); Nappe, 97 N.J. at 49. Hence, the trial court properly granted
summary judgment to Western on plaintiff's punitive damages claim.
A-3914-23 64 Similar reasoning pertains to the punitive damages sought against
Gloucester. We need not repeat here the rationale concerning Western above.
Many of those same factual events within the chronology extend to Gloucester 's
managers and supervisors as well. Suffice it to say that there is insufficient
evidence to support the imposition of punitive damages against Gloucester, even
viewing the record in a light most favorable to plaintiffs.
III.
To the extent we have not addressed them, all other arguments raised by
plaintiffs lack sufficient merit to warrant discussion in this opinion. R. 2:11-
(e)(1)(E).
For the reasons stated, we reverse the entry of summary judgment on
liability as to both defendants, and remand for further proceedings. We affirm,
however, the court's construction of Gloucester's general release and also its
denial of punitive damages.
Reversed in part, affirmed in part, and remanded. We do not retain
jurisdiction.
A-3914-23 65
Related
Cite This Page — Counsel Stack
Michael Hatty v. Western Industries-North, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/michael-hatty-v-western-industries-north-llc-njsuperctappdiv-2026.